Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.08), Briefing.com reports. During the same quarter in the prior year, the firm earned ($0.45) EPS.

Genocea Biosciences (NASDAQ GNCA) traded down $0.05 during mid-day trading on Friday, hitting $1.05. 884,474 shares of the stock traded hands, compared to its average volume of 2,050,000. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.97 and a current ratio of 2.97. Genocea Biosciences has a twelve month low of $1.04 and a twelve month high of $7.29.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/genocea-biosciences-inc-gnca-issues-quarterly-earnings-results/1678966.html.

Several equities research analysts have commented on the stock. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, July 24th. Cowen and Company reissued an “outperform” rating and set a $40.00 target price on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Piper Jaffray Companies reissued an “overweight” rating and set a $5.00 target price on shares of Genocea Biosciences in a research note on Thursday. ValuEngine lowered shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Finally, Stifel Nicolaus lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $15.00 to $2.50 in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $7.62.

An institutional investor recently raised its position in Genocea Biosciences stock. State Street Corp raised its holdings in Genocea Biosciences, Inc. (NASDAQ:GNCA) by 1,595.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 366,172 shares of the biotechnology company’s stock after acquiring an additional 344,572 shares during the period. State Street Corp owned approximately 1.28% of Genocea Biosciences worth $1,912,000 at the end of the most recent quarter. Institutional investors own 57.39% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Earnings History for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.